# OMAHA-003 (NCT06136624)

> Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

No report yet. It can be ordered.

- Drugs tested: opevesostat
- Indication: mCRPC after NHA and taxane-based chemotherapy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06136624
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Prostate Cancer Metastatic
- Interventions: Opevesostat; Abiraterone acetate; Enzalutamide; Hydrocortisone; Fludrocortisone acetate; Prednisone; Dexamethasone
- Enrollment: 1310
- Primary outcome: Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants
- Primary outcome: OS in AR LBD Mutation-Negative Participants

## Indexed commentary on OMAHA-003 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- YouTube: 1
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=omaha-003-nct06136624